Never touch the cleaned area with your fingers, and never reuse needleseach injection requires a sterile, unused needle and syringe
AOD 9604 enhances fat burning while growth hormone peptides preserve/build muscle and improve recovery
Some protocols involve longer continuous use for 6-12 months with ongoing monitoring
In children, decreased levels of intrinsic factor can be an inherited (genetic) condition
Mechanism of Action Compared AOD-9604, Semaglutide and tesamorelin act on three separate biological systems direct lipolytic activity, GLP-1 receptor signaling, and GHRH-driven pituitary stimulation, respectively which is why researchers rarely treat them as interchangeable despite their shared association with fat metabolism
AOD-9604 and Tesamorelin in Combination Research The theoretical basis for discussing AOD-9604 alongside Tesamorelin comes from their non-overlapping mechanisms: AOD-9604 acts locally on fat tissue without engaging the GH/IGF-1 axis, while Tesamorelin works upstream by stimulating pituitary GH release